In the present preliminary study we explored the possibility of an anticonvulsant effect of normal human immunoglobulin in an animal epilepsy model based on direct cortical stimulation in freely moving rats. After human immunoglobulin administration a significant and prolonged elevation of the threshold for convulsions was measured in 12% (6/49) of the total group of outbred Wistar rats. In the subgroup of more than seven months old Wistar rats this was 67% (6/9). When a threshold increasing effect of immunoglobulin occurred, it was detectable within 0.5-l hour after administration, reached its maximum after approximately two hours and continued for at least 40 hours.
INTRODUCTION
Normal human immunoglobulin (IVIg) initially used for substitution of immunodeficiency syndromes has recently been reported to be effective in an increasing amount of diseases thought to be produced by immunopathology'**.
Although epiIepsy is one of the oldest applications of IVIg in neurological diseases3, and although positive results have been published, IVIg treatment of intractable epilepsies, nevertheless, remains controversia14: on the one side the various studies on IVIg in human epilepsy could not provide an indication for an immunological mechanism of action of IVIg4, on the other side it has been stated without published data that IVIg lacks an anticonvulsant effect?. In the present study we explored the possibility of an anticonvulsant effect of IVIg in an animal epilepsy model based on direct cortical stimulation in freely moving rats6*'. In the subgroup in which IVIg was ineffective we investigated whether this was due to an inability of IVIg to cross the blood-brain barrier. The anticonvulsant efficacy was tested and quantified using direct cortical stimulation with a ramp-shaped pulse train as described in detail elsewhere-. The threshold for localized seizure activity (TLS) has been used to quantify anticonvulsant effects. The TLS was defined as the current at which the first mild clonic forepaw movements appeared. TLS stimulation was stopped at this point and further convulsive activity was then immediately aborted. In this way a postictal threshold increase was avoided. Before IVIg administration, the TLS was determined five times at five minute intervals, to determine the average baseline value. Shortly after i.p. IVIg injection, TLS determination was performed, and during three days the TLS was measured at regular intervals. TLS changes were expressed as elevation over the baseline value in PA. All test sessions were recorded on video. Before IVIg experiments were carried out, the animals were tested twice daily for two weeks to stabilize the threshold'. The effect of IVIg on TLS was tested in more than seven months old rats (n = 9), and in younger rats (3-4.5 months, n = 40). Some rats of the younger age group (n = 10) were treated previously with carbamazepine (40 mg/kg), others (n = 30) were drug-naive.
In addition, we investigated (n = 3) whether IVIg was ineffective due to an inability to cross the blood-brain barrier: two days after IVIg administration rates were killed, and brains were freshly fixed in formaldehyde-sublimate at 4°C for 24 hours. After dehydration tissue was embedded in paraplast and four micron sections were cut using a Jung 2050 microtome. Dewaxed poly-Llysine mounted sections were incubated with human IgG antiserum (gamma chain specific, Dakopatts) for 48 hours at 4°C in a dilution of l/250. Immunohistochemical staining was performed using the avidin-biotin-peroxidase and the avidin-biotin-alkaline-phosphatase complex technique (ABC) according to the manufacturer instructions (Vector). All antibody dilutions were made in 0.05 M phosphate buffered saline (PBS) to which 0.1% Triton-X-100 was added. As negative controls we used rats (n = 3) that also had experienced seizures due to cortical stimulation but without administration of human IVIg.
RESULTS
After human immunoglobulin administration (500 mg/kg; Table 1 ) a significant and longlasting increase in TLS was measured in 12% (6/49) of the total group of outbred Wistar rats. In the subgroup of more than seven months old Wistar rats this was 67% (6/9), in the other subgroup this was 0% (O/40) (Fisher exact test (P <O.OOOl), Table 1 ). Figure 1 depicts the typical time-effect relationship in an animal showing an increase in TLS. When a TLS increasing effect of IVIg occurred, it was detectable within 0.5-l hour after administration, reached its maximum after approximately two hours and continued for at least 40 hours.
In the subgroup (n = 40) of 3-4.5 months old rats, neither three different doses of IVIg (400, 1000, 1500mg/kg), nor pretreatment with carbamazepine (40mg/kg) showed any effect on TLS.
In control rats (with cortical stimulation, without IVIg treatment) immunohistochemical staining for human IgG was negative (Fig. 2a) , whereas in all (non-responding) rats (n = 3) killed two days after IVIg administration, staining for human IgG was present in brain capillaries, chorioid plexus, and in brain tissue around blood vessels (Fig. 2b) . Some neuronal and glial cells showed immunohistochemical staining. Thus, the lack of a threshold increasing effect by IVIg was not due to an inability of IgG to cross the blood-brain barrier.
DISCUSSION
These preliminary investigations indicate that human IVIg has the potential to raise the threshold for convulsions in rats. Already within the first hour after i.p. administration a significant and prolonged anticonvulsant effect occurred in 12% of all tested outbred Wistar rats. In the subgroup of more-than-seven-months-old Wistar rats this percentage was 67%, which suggests an age-related effect of the IVIg response. An age-related effect of epilepsy itself has been reported previously: seizure intensity increased with increasing age in genetically epilepsy-prone ratsg. The present study confirmed the results of the only other study on administration of human IVIg in an animal epilepsy model (kindled cats)". In the latter study and in our study a similar time-effect relationship and a similar immunohistochemical staining pattern for human IgG were animals, and the capability of IgG to cross the blood-brain barrier in IVIg-responding and nonresponding animals.
